Table S2.
Estimated average duration of LARC use
| LARC | Expected length of use in years (cycles) | Annual removal rate (% of women)
|
Average duration (number of years) | Average duration (number of cycles) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | ||||
| MIR | 5 (60) | 25.3% | 13.3% | 8.4% | 6.0% | 3.9% | n/a | n/a | n/a | 3 | 37 |
| IMP/NEXP | 3 (36) | 22.5% | 14.5% | 9.0% | n/a | n/a | n/a | n/a | n/a | 2 | 29 |
| IUD† | 8 (96) | 21.6% | 13.4% | 11.8% | 9.1% | 5.7% | 1.0% | 1.0% | 1.0% | 4 | 51 |
| DEPO | 0.3 (3) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.3 | 3 |
| NOR | 0.2 (2) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.2 | 2 |
Notes:
†
Based on T-Safe CU380A. Reproduced from: National Collaborating Centre for Women’s and Children’s Health. Long-Acting Reversible Contraception. NICE Clinical Guideline No.30. London: RCOG Press; 2013, with the permission of the Royal College of Obstetricians and Gynaecologists.1
Abbreviations: DEPO, Depo-Provera; IMP, Implanon; IUD, Intrauterine device; LARC, long-acting reversible contraceptive; MIR, Mirena; NEXP, Nexplanon; NOR, Noristerat.